Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in Patients with Relapsed or Refractory B-Cell Malignancies

Blood (2022) 140 (Supplement 1): 6498–6500.

https://doi.org/10.1182/blood-2022-163683

Published: 2022

Journal Articles

A Phase 1a/b Dose Escalation Study of the FLT3/BTK Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Aaron D Goldberg, Maro Ohanian, Paul B. Koller, Mohamad Cherry, Jessica K. Altman, Benjamin Tomlinson, Namrata Sonia Chandhok, Donna Nguyen Haney, Jia Hu, Ranjeet Kumar Sinha, William G Rice, Rafael Bejar

Blood (2022) 140 (Supplement 1): 6220–6221.

https://doi.org/10.1182/blood-2022-167759

Published: 2022

Journal Articles

A Phase 1/2 Dose Escalation Study of the Myeloid Kinase Inhibitor HM43239 in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Naval Daver, Kyoo Hyung Lee, Brian A. Jonas, Martha L. Arellano, Chul W. Jung, Sang Kyun Sohn, Sung-Soo Yoon, Jeong-Ok Lee, Jia Hu, Ranjeet Kumar Sinha, William G Rice, Rafael Bejar

Blood (2022) 140 (Supplement 1): 6197–6199.

https://doi.org/10.1182/blood-2022-167972

Published: 2022

Journal Articles

Novel R41Q- and R46Q-PAR1-Modified Mice Enable Proof-of-Concept Studies for In Vivo Protective Mechanisms of Action for Activated Protein C (APC) in Sepsis and Stroke

Ranjeet Kumar Sinha, PhD MSc, Yaoming Wang, PhD, Zhen Zhao, PhD, Jose A. Fernandez, MD PhD, Naveen Gupta, Xiao Xu, MSc, Greg Martin, MSc, Sergey Kupriyanov, PhD MSc, Laurent O Mosnier, PhD, Berislav Zlokovic, PhD, John H. Griffin, PhD

Blood (2016) 128 (22): 13.

https://doi.org/10.1182/blood.V128.22.13.13

Published: 2016

Journal Articles

Activated Protein C (APC) Therapy Ameliorates Chronic Graft Versus Host Disease By Cell Signaling Mechanisms That Require Cleavage at Arg46 in PAR1 on T Cells

Ranjeet Kumar Sinha, PhD MSc, Ryan P Flynn, PhD, Jose A. Fernandez, MD PhD, Xiao Xu, MSc, Greg Martin, MSc, Sergey Kupriyanov, PhD MSc, John H. Griffin, PhD, Bruce R. Blazar, MD

Blood (2016) 128 (22): 808.

https://doi.org/10.1182/blood.V128.22.808.808

Published: 2016

Journal Articles

Plasma Constitutive Serum Amyloid A4 Is Procoagulant and Is Elevated in Venous Thrombosis Patients

John H. Griffin, PhD, Jose A. Fernandez, MD PhD, Ranjeet Kumar Sinha, PhD MSc, Darlene J. Elias, MD, Hiroshi Deguchi, MD PhD

Blood (2015) 126 (23): 3486.

https://doi.org/10.1182/blood.V126.23.3486.3486

Published: 2015

Journal Articles

Exome Genotyping Links Venous Thrombosis Risk with the Skeletal Muscle Myosin Gene Cluster and Leads to Discovery of New Family of Procoagulant Factors

Hiroshi Deguchi, MD PhD, Ranjeet Kumar Sinha, PhD MSc, Darlene J. Elias, MD, John H. Griffin, PhD

Blood (2015) 126 (23): 763.

https://doi.org/10.1182/blood.V126.23.763.763

Published: 2015

Journal Articles

Novel R41Q-PAR1-Modified Mice Enable Proof-of-Concept Studies for in Vivo Mechanisms of Action for Thrombin (IIa) and Activated Protein C (APC)

Ranjeet Kumar Sinha, PhD, Laurent Burnier, PhD, Naveen Gupta, MD, Xiao Xu, MS, Sergey Kupriyanov, PhD, Greg Martin, MS, Laurent O. Mosnier, PhD, John H. Griffin, PhD

Blood (2014) 124 (21): 99.

https://doi.org/10.1182/blood.V124.21.99.99

Published: 2014

Journal Articles

Activated Protein C Cytoprotective Signaling in Endothelial Cells Involves apoER2 and Disabled-1

Ranjeet Kumar Sinha, PhD, Xia Yang, PhD, Laurent O. Mosnier, PhD, John H. Griffin, PhD

Blood (2012) 120 (21): 1102.

https://doi.org/10.1182/blood.V120.21.1102.1102

Published: 2012

Journal Articles

Protection Against Vascular Leakage in Vivo by a Peptide Mimetic of the Novel Tethered Ligand Generated by Non-Canonical Cleavage of Protease Activated Receptor 1 by Activated Protein C

Laurent Burnier, PhD, Ranjeet Kumar Sinha, PhD, Eveline A. Bouwens, PhD, John H. Griffin, PhD, Laurent O. Mosnier, PhD

Blood (2012) 120 (21): 497.

https://doi.org/10.1182/blood.V120.21.497.497

Published: 2012

NARROW

A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in Patients with Relapsed or Refractory B-Cell Malignancies

A Phase 1a/b Dose Escalation Study of the FLT3/BTK Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

A Phase 1/2 Dose Escalation Study of the Myeloid Kinase Inhibitor HM43239 in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Novel R41Q- and R46Q-PAR1-Modified Mice Enable Proof-of-Concept Studies for In Vivo Protective Mechanisms of Action for Activated Protein C (APC) in Sepsis and Stroke

Activated Protein C (APC) Therapy Ameliorates Chronic Graft Versus Host Disease By Cell Signaling Mechanisms That Require Cleavage at Arg46 in PAR1 on T Cells

Plasma Constitutive Serum Amyloid A4 Is Procoagulant and Is Elevated in Venous Thrombosis Patients

Exome Genotyping Links Venous Thrombosis Risk with the Skeletal Muscle Myosin Gene Cluster and Leads to Discovery of New Family of Procoagulant Factors

Novel R41Q-PAR1-Modified Mice Enable Proof-of-Concept Studies for in Vivo Mechanisms of Action for Thrombin (IIa) and Activated Protein C (APC)

Activated Protein C Cytoprotective Signaling in Endothelial Cells Involves apoER2 and Disabled-1

Protection Against Vascular Leakage in Vivo by a Peptide Mimetic of the Novel Tethered Ligand Generated by Non-Canonical Cleavage of Protease Activated Receptor 1 by Activated Protein C

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only